# Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer

> **NCT02732327** · PHASE2 · TERMINATED · sponsor: **Forest Laboratories** · enrollment: 2 (actual)

## Conditions studied

- Neoplasms
- Febrile Neutropenia

## Interventions

- **DRUG:** CAZ-AVI
- **DRUG:** Vancomycin
- **DRUG:** Linezolid
- **DRUG:** Cefepime
- **DRUG:** Meropenem
- **DRUG:** Piperacillin/tazobactam

## Key facts

- **NCT ID:** NCT02732327
- **Lead sponsor:** Forest Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-05-17
- **Primary completion:** 2016-06-27
- **Final completion:** 2016-06-27
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** No longer aligned with the revised clinical development plan and commercial strategy
- **Last updated:** 2017-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02732327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02732327, "Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02732327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*